Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection

Study Identifier:
ACH443-003
ClinicalTrials.gov Identifier:
NCT00034359
EudraCT Identifier:
N/A
EU CT ID:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete

Study Details

Medical Condition
  • Hepatitis
Study Drug
  • Drug: ACH-126,443
  • Drug: Lamivudine
  • Drug: Placebo
Date
Feb 2002 - Jan 2003
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years

Study Details

Medical Condition
  • Hepatitis
Study Drug
  • Drug: ACH-126,443
  • Drug: Lamivudine
  • Drug: Placebo
Date
Feb 2002 - Jan 2003
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information

Protocol Summary

The purpose of this study was to determine the safety and anti-hepatitis B virus (-HBV) activity of ACH-126,443 in comparison to lamivudine or placebo in treatment-naive adults with chronic hepatitis B infection.

Trial Locations

Location
Status
Location
Clinical Trial Site
Sofia, Bulgaria
Status
N/A
Location
Clinical Trial Site
Belgrade, Unmapped
Status
N/A
Location
Clinical Trial Site
Novi Sad, Unmapped
Status
N/A